Physician profile
Emily Ward
NPI 1144750894
$6,766.71
in general payments reported to CMS, 2019-2025
24 companies · $1,810 in 2025
The $1,810 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $928 · 2022: $1,453 · 2023: $1,001 · 2024: $1,575 · 2025: $1,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,061 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,060.88 |
| Education | $324.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,402.22 | 2021-2025 | |
| Janssen Biotech, INC. | $904.41 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $733.47 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $726.20 | 2021-2025 | |
| Lilly USA, LLC | $595.55 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $497.84 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $448.89 | 2021-2025 | |
| Pfizer INC. | $296.70 | 2021-2025 | |
| Amgen INC. | $169.60 | 2023-2025 | Otezla, Otezla |
| Organon LLC | $156.21 | 2024-2025 | Hadlima |
| E.R. Squibb & Sons, L.L.C. | $135.20 | 2022-2023 | Sotyktu |
| Genzyme Corporation | $121.69 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Incyte Corporation | $92.59 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $79.85 | 2021-2023 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $69.17 | 2024 | Vtama |
| Genentech USA, INC. | $47.44 | 2021-2022 | |
| Kyowa Kirin, INC. | $43.68 | 2024 | Poteligeo |
| Organogenesis INC. | $42.98 | 2024 | |
| Paratek Pharmaceuticals, INC. | $29.38 | 2025 | Nuzyra |
| Galderma Laboratories, L.P. | $26.24 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.83 | 2022 | |
| Smith+Nephew, INC. | $16.11 | 2025 | Collagenase Santyl |
| Arcutis Biotherapeutics, INC. | $14.47 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.